INTRODUCTION:

Designing a high-quality product and its production process is the goal of pharmaceutical development in order to fulfil the product's intended performance consistently. Scientists can establish the design space, requirements, and production controls with the help of information and knowledge gathered from pharmaceutical development studies and manufacturing experience. Quality risk management may be based on data from pharmaceutical development research. It is crucial to understand that quality cannot be tested into things; instead, it must be included through design. Adjustments in manufacturing and formulation procedures made during the development and lifecycle management process should be viewed as chances to learn more and advance the design space's establishment. Like how incorporating pertinent information learned from tests yielding unexpected results might.¹

Definition:^2,3

Quality: Quality is a crucial term in Quality by Design. The process of establishing and maintaining connections via the assessment, foresight, and satisfaction of expressed as well as inferred requirements is known as "quality."

Quality by Design:^4,5,6,7

A strategic method for production and development is called quality by design (QbD). Its purpose is to guarantee that a drug product's intended performance, both in terms of purity and effectiveness, is as anticipated. Well-defined objectives and effective risk management are necessary for achieving this.

A detailed grasp of the technical process, the factors that impact the process, and the performance envelope in which those variables must stay in order to accomplish the goals is part of quality by design. Because to the product's constant safety and efficacy, QbD benefits both the producer and the user (since quality and costs will be well understood, controlled and predictable).

Pharmaceutical industries are aware of the product's effectiveness, safety, and quality. By using scientific methods known as QbD, product quality has increased (Quality by Design). From product creation through production, scientific methodologies may provide the precise and adequate knowledge. By boosting production and quality, these QbD tools will reduce risk. The QbD technique has been effectively implemented in the creation of standard formulations today.

Figure 1 Product Quality

Pharmaceutical Quality by Design (QbD) is a methodical approach to development that starts with established objectives and places an emphasis on product and process knowledge and control based on solid science and quality risk management. The following objectives of pharmaceutical QbD may be present:

1. To achieve significant product quality requirements based on clinical performance.

2. To improve product and process design, knowledge, and control in order to maximise process capability and decrease product variability and flaws.

3. Improve the effectiveness of product development and production.

4. Strengthen post-approval change management and root cause analysis.

These objectives may frequently be met under QbD by tying desirable clinical performance to product quality, then developing a solid formulation and manufacturing procedure to reliably provide the required product quality.

The FDA has made tremendous strides in achieving the first goal, performance-based quality requirements, since the start of pharmaceutical QbD. The size of the beads in capsules marked for sprinkle and the scoring of tablets are two instances of FDA regulations. Recent FDA debates on the physical characteristics of generic medicine items and the tested potency limitations for medications with restricted therapeutic indices reflect this trend. Although this was acknowledged in a recent scientific publication, it should be noted that ICH documents did not expressly identify clinical performance-based requirements as a QbD objective.

The second goal of pharmaceutical quality by design is to improve process capabilities and decrease product variability, which frequently results in product flaws, rejections, and recalls. A method and product that are robustly developed are necessary to achieve this goal. Also, a better understanding of products and processes might make it easier to recognise and manage variables affecting the quality of medicinal products. In order to decrease product variability, flaws, rejections, and recalls, efforts should be made to continue improving the process after regulatory clearance.

QbD employs a methodical approach to product development. As a result, it improves formulation design, development speed, and capabilities. Moreover, it moves resources from an upstream proactive mode to a downstream corrective mode. It improves the manufacturer's capacity to pinpoint the underlying reasons behind manufacturing failures. Hence, improving manufacturing and product development efficiency is pharmaceutical QbD's third goal.

Enhancing root cause analysis and post approval change management is QbD's goal. The capacity to quickly scale-up and do root cause analysis is constrained without a solid grasp of the product and the process, and thus necessitates the creation of additional data sets on the suggested bigger size. The FDA's change guidelines offer a structure for modifications made after approval. An FDA recommendation was recently released with the goal of lowering the regulatory reporting requirements for certain low-risk CMC (chemistry, manufacturing, and control) post-approval manufacturing adjustments.

Elements of Pharmaceutical Quality by Design:⁸

In a pharmaceutical QbD approach to product development, an applicant identifies qualities that are crucial to quality from the perspective of the patient, translates them into the critical quality attributes (CQAs) of the drug product, and establishes the relationship between formulation/manufacturing variables and CQAs to reliably deliver a drug product with such CQAs to the patient. The components of QbD are as follows:

1. A quality target product profile (QTPP) that lists the drug product's crucial quality characteristics (CQAs).

2. Product design and knowledge, such as identifying crucial material characteristics (CMAs).

3. Process design and comprehension, which includes identifying important process parameters (CPPs) and having a solid grasp of scale-up principles that connect CMAs and CPPs to CQAs.

4. A plan of action that specifies the drug's characteristics.

Pharmaceutical Quality by Design Tools:^9,10,11

Prior Knowledge:

The phrase "prior knowledge" has been widely used in workshops, seminars, and presentations even though it is not formally defined. In regulatory filings, applicants frequently make an effort to substitute previous knowledge for undertaking requisite scientific investigations or providing "legitimate" arguments for doing so.

A familiarity with someone or something may be referred to as knowledge, which can also include information, facts, descriptions, and/or abilities gained via training or education. With the phrase "prior knowledge," the word "prior" refers not just to something that has already happened but also to anything that is private and not generally known. As a result, previous knowledge cannot be acquired for the purposes of this article through education but only by experience. Public knowledge is information that has been acquired via schooling or widely available books. general prior experience with the QbD framework.

Risk Assessment:¹²

The production and use of a medicinal product, including its components, "necessarily include some degree of risk," according to ICH Q9 quality risk management. The degree of effort, formality, and documentation of the quality risk management process should be proportionate with the level of risk, and the appraisal of the risk to quality should be founded on scientific knowledge and eventually lead to the protection of the patient (4). The aim of ICH Q9 is to provide a systematic approach to quality risk management; risk assessment in product development is not expressly addressed. Nevertheless, risk assessment in product development may also be done using the risk assessment techniques mentioned in ICH Q9.

Prior to development studies, risk assessments are conducted to identify formulation and process factors that may be high-risk and may have an influence on the final product's quality. It is frequently motivated by information gaps or ambiguity and aids in prioritising which investigations are necessary. The development of a control plan is facilitated by the study results, which identify the factors that are crucial and those that are not. Identification of the factors to be studied experimentally is the result of the risk assessment. The following is a partial list of popular risk assessment tools that is provided by ICH Q9:

· Simple techniques for risk management facilitation (flowcharts, check sheets, etc.)

· Analysis of fault trees.

· Ranking and filtering of risks.

· Risk analysis and important control points (hazard analysis and preliminary hazard analysis)

· Analysis of failure mode and effects.

· Mode of failure.

Regulatory Challenges and Inspection:^13,14,15

Because there are broader ranges and restrictions based on product and process expertise in a QbD approach, the regulatory burden is reduced. Modifications that stay within these parameters don't need prior permission. Inspections have historically been carried out in line with CDER's compliance programme "Inspection of approved Bio-logical Therapeutical Drug Product and the FDA system-based approach. Using a QbD approach, the FDA inspection team will evaluate the application and efficacy of the process design during prelicense and preapproval inspections. The inspection will assess the efficiency of the quality system in ensuring consistent product quality, adapting control methods, and streamlining processes. Businesses Wanted FDA clarification on QbD terms, approved techniques, selection criteria for Key Quality Attributes, and requirements to help with adequacy.

Benefits of Implementing QbD for FDA:^16,17

· The Question-based Review (QbD) approach has been used at the CDER's office of generic medicines in order to: Improve Manufacturing efficiency; Reduce Cost; Reduce Project Rejections; Eliminate Waste.

· The QbD implementation for the biological licencing application (BLA) is moving forward.

· Using Quality by Design as a 2 complete factorial design, optimisation design was carried out.

· Learning inside an organisation is an investment in the future.

Benefits to Industry:

· Improved interactions with the FDA deal on a science level rather than a procedural one; improved product design with fewer manufacturing difficulties.

· The QbD technique produced nanocellulose with enhanced flow and compatibility properties.

Design Space:^17,18

The collection of all possible combinations of a technique's input variables that have been shown to guarantee the quality of the data the method produces is known as the design space. Design space might be built for one operation, many operations, or the whole process. The criticality of factors and their ranges are identified using the risk assessment, past experiments, and multivariate factor screening methods in order to create a design space. With a pharmaceutical product, more than one design space could exist. The ideal method for creating design space is experimental design at the lab/pilot size, which is then extrapolated to exhibit/commercial scale by creating a correlation with the aid of scale-independent factors.

Figure 2. Quality by Design

CONCLUSION:

As more pharmaceutical products are developed, Quality by Design (QbD) is becoming as a significant and popular method. improves production while giving patients high-quality medications. The QbD framework and its tools highlight the requirements of the contemporary manufacturing process. A time and money-effective method to design and manufacturing is quality by design. A broad range of biotechnological goods, including vaccines, enzymes, monoclonal antibodies, etc., are also covered by QbD. In the future, there will be considerably more regulatory freedom thanks to this new Quality by Design (QbD) methodology. Moreover, Quality by Design has expanded well beyond pharmaceuticals to become a production paradigm that may be used in a variety of industries.

REFERENCES:

1. Nadpara NP, Thumar R V, Kalola VN, Patel PB. Review Article Quality By Design (Qbd): A Complete Review. 2012; 17(2): 20–8.

2. Woodcock J. The concept of pharmaceutical quality American Pharmaceutical Review. 2004; 7(6): 10–5.

3. Chavan SD, Pimpodkar N V, Kadam AS, Gaikwad PS, Pharm PD. Research and Reviews: Journal of Pharmaceutical Quality Assurance Quality by Design. 2015; 1(2): 18–24.

4. Woodcock J. The concept of pharmaceutical quality American Pharmaceutical Review. 2004; 7(6): 10–5.

5. Mimansha Patel: Review article: Quality by Design (QbD). Indo American Journal of Pharmaceutical Research. 2018; 8(11): 1357-60.

6. Satish K. Mandlik. Iimplementation of Quality by Design (QBD) approach in formulation and Development of Ritonavir Pellets using Extrusion Spheronization method. International J of Applied Pharma. 2020; 12(1): 139 –146.

7. FDA Guidance for Industry and Review Staff: Target Product Profile – A Strategic Development Process Tool (Draft Guidance).

8. Roy S. Quality by Design-Holistic concept of concept of building quality in pharmaceuticals. Int. J Pham Biomed Res. 2012; 3:100-108.

9. Woodcock J. The concept of pharmaceutical quality. American Pharmaceutical Review. 2004; 7(6): 10–5.

10. Roy S. Quality by Design-Holistic concept of concept of building quality in pharmaceuticals. Int. J Pham Biomed Res. 2012; 3: 100-108.

11. Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2006.

12. Lionberger RA, Lee LS, Lee L, Raw A, Yu LX. Quality by design: Concepts for ANDAs. The AAPS Journal. 2008; 10: 268–276.

13. Mayur Ashok Chordiya, Hemant Hiraman Gangurde and Vikram Nirmal Sancheti. Quality by design: A Roadmap for quality pharmaceutical products. Journal of Reports in Pharmaceutical Science. 2019; 8(2): 289-94.

14. Jain S. Quality by Design (QbD): A comprehensive understanding of implementation and challenges in pharmaceutical development. Indian Journal of Pharmaceutical Sciences. 2013; 6: 29-35.

15. Satish K. Mandlik. Iimplementation of Quality by Design (QBD) approach in formulation and Development of Ritonavir Pellets using Extrusion Spheronization method. International J of Applied Pharma. 2020; 12(1): 139 –146.

16. Dra Kulich. A Critical Challenges to implementing QbD: AQ&A with FDA. Pharm Technol. 2009; 33: 90-4.

17. Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2006.

18. Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2007

Received on 19.06.2023 Modified on 18.12.2023

Res. J. Pharmacology and Pharmacodynamics. 2024;16(2):119-122.

DOI: 10.52711/2321-5836.2024.00021

Risk Assessment:12

Risk Assessment:¹²